• About us
• Contact

Advertisement

Organisation › Details

Protagen (Group)

Protagen AG (www.protagen.de) is an international leading specialist in the fields of diagnostics and GMP-compliant protein analysis. The innovations of Protagen are UNIarray®, a technology platform for the development of novel serum based diagnostics, as well as UNIchip®, a versatile product family of protein microarrays for faster development of antibodies. *

 

	Start	1997-01-01 established
	Group	Freenome (Group)
	Today	Protagen AG
	Industry	diagnostics (medical/biological)
	Industry 2	protein chip product (array, bead, lab-on-a-chip)
	Person	Lautscham, Georg (Protagen 201610– CEO before CBO)
	Person 2	Schulz-Knappe, Peter (Protagen 201001– head Protein Services before Proteome Sciences plc CEO before BioVisioN CEO)
	Region	Dortmund
	Country	Germany
	Street	15 Otto-Hahn-Str.
	City	44227 Dortmund
	Tel	+49-231-9742-6300
		Address record changed: 2020-12-02
Basic data	Employees	B: 11 to 50 (2014-11-08)
		* Document for »About Section«:
		Record changed: 2023-12-30

Advertisement

More documents for Freenome (Group)

• [1] Freenome, Inc.. (2/15/24). "Press Release: Freenome Raises $254 Million in New Funding to Accelerate its Platform for Early Cancer Detection". South San Francisco, CA....
• [2] Freenome, Inc.. (5/22/23). "Press Release: Freenome Acquires Global Immunodiagnostics Developer Oncimmune Ltd". South San Francisco, CA....
• [3] Freenome, Inc.. (12/7/21). "Press Release: Freenome Raises $300M in Series D Financing to Advance Multiomics Platform for Early Cancer Detection". South San Francisco, CA....
• [4] Freenome, Inc.. (12/1/21). "Press Release: Freenome Partners with Siemens Healthineers for Breast Cancer Research". South San Francisco, CA....
• [5] Biognosys AG. (11/9/21). "Press Release: Biognosys Launches Next-Generation Blood Biomarker Discovery Solution". Schlieren....
• [6] Freenome, Inc.. (8/26/20). "Press Release: Freenome Closes $270 Million Series C Financing to Advance Novel Multiomics Blood Testing Platform for Early Cancer Detection". South San Francisco, CA....
• [7] Oncimmune Holdings plc. (9/20/19). "Press Release: €8.5m Credit Facility Secured. Funding to Accelerate the Further Commercialisation of Oncimmune’s Lead Products and Services"....
• [8] ADC Therapeutics S.A.. (8/26/19). "Press Release: ADC Therapeutics and Freenome Enter Biomarker Development Collaboration". Lausanne & South San Francisco, CA....
• [9] Freenome, Inc.. (7/24/19). "Press Release: Freenome Closes $160 Million Series B Financing to Advance Its Multiomics Blood Testing Platform for Early Cancer Detection". South San Francisco, CA....
• [10] Oncimmune Holdings plc. (3/19/19). "Press Release: Oncimmune Announces the Acquisition of Protagen Diagnostics AG, a Leader in Personalised Immuno-Profiling". Cambridge, MA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.